Xtant Medical Holdings, Inc.

AMEX:XTNT

Medical - Devices

Healthcare
$0.36 -0.16%

-$0.00 today

Market cap
$50.37M
Beta
-0.17
P/E (TTM)
33.4
EPS (TTM)
$0.01
52W Low $0.40High $0.95

Volume 0.16M

Average 0.16M

XTNT Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Xtant Medical Holdings, Inc.AMEX: XTNT

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $746K fell 1.6% year over year, ahead of the -27.4% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 2.6% from the prior quarter. Over 3 fiscal years it compounded at +5.5% a year.

Context

  • Stock-based compensation amounted to 2.2% of revenue in FY2025, down 1.4 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -1.6% holds above the trailing-twelve-month pace of -27.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$746K+2.6% QoQ
Last fiscal yearDec 2025
$2.89M-29.8% YoY
LTMMar 2026
$2.88M-27.4% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.6%——
1 year-29.8%——
3-year CAGR+5.5%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
2.89M USD
Year-over-year change
-29.8%
4-year CAGR
+7.0%

Stock-Based Compensation vs competitors

How XTNT compares with its peers on the latest reported figures

  • XTNT's LTM Mar 2026 stock-based compensation of $2.88M is the 4th largest of the 8 companies compared; the peer median is $2.17M.
  • Its year-over-year change of -27.4% is the 5th highest of 7, against a peer median of -0.0%.
  • Stock-based compensation amounts to 2.4% of revenue for XTNT, versus a peer median of 11.0%.
XTNT Competitors Peer median
Stock-Based Compensation for XTNT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LUCDLucid Diagnostics Inc.LTM Mar 2026$2.3B +49501.8%-33.1%44751.8%
RCELAVITA Medical, Inc.LTM Mar 2026$7.93M -41.7%+10.8%11.0%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$4.21M +10.0%+0.1%12.3%
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$2.88M -27.4%+5.5%2.4%
EXOZeXoZymes, Inc.LTM Mar 2026$2.17M +67.1%+109.4%—
VANIVivani Medical, Inc.LTM Mar 2026$1.45M -10.0%+4.6%—
APYXApyx Medical CorporationLTM Mar 2026$1.02M -69.4%-33.1%1.8%
FONRFONAR CorporationLTM Mar 2026$0 ——0.0%
Peer median (excluding XTNT) $2.17M-0.0%+2.4%11.0%

Competitors are the stored peer set for XTNT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(4.85M)(8.49M)660K(16.45M)4.97M
Depreciation & Amortization1.33M1.29M3.17M4.22M5.22M
Deferred Income Tax00(1.9M)21K0
Stock-Based Compensation2.21M2.46M2.74M4.12M2.89M
Change in Working Capital793K(2.81M)(3.63M)(5.35M)(3.05M)
Accounts Receivables(319K)(3.94M)(8.74M)(755K)(591K)
Inventory2.62M(1.15M)(1.89M)(2.49M)(2M)
Accounts Payables(332K)875K2.98M1.03M(3.12M)
Other Working Capital(1.18M)1.41M4.01M(3.13M)2.66M
Other Non-Cash Items954K2.2M(10.55M)1.54M2.5M
Operating Cash Flow439K(5.34M)(9.52M)(11.9M)12.55M
Capital Expenditures(2.12M)(1.76M)(1.46M)(4.11M)(2.38M)
Acquisitions (Net)00(23.5M)00
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities225K205K175K383K10.28M
Investing Cash Flow(1.89M)(1.56M)(24.78M)(3.73M)7.9M
Debt Repayment(592K)(291K)6.18M12.43M(9.33M)
Common Stock Issued18.43M9.31M14.01M4.46M0
Common Stock Repurchased0000(65K)
Dividends Paid00000
Other Financing Activities(337K)9.07M(500K)(816K)(175K)
Financing Cash Flow17.5M9.02M19.69M16.07M(9.57M)
Effect of Forex Changes0024K(149K)232K
Net Change in Cash16.05M2.12M(14.58M)298K11.11M
Free Cash Flow(1.68M)(7.11M)(10.97M)(16.01M)10.16M

Xtant Medical Holdings, Inc.

AMEX:XTNT

Intrinsic Alpha fair value

Locked

Current Price

$0.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.